Inactivation by the mutation or deletion of ETV6, RUNX1, and GATA3 has also been described in patients with Acute Myeloid Leukemia (AML) and correlates with poor outcomes in ETP-ALL [4,8,14]. Here, RUNX1 is linked to acute myeloid leukemia.